Literature DB >> 7251906

Relation between concentrations of metronidazole and Bacteroides spp in faeces of patients with Crohn's disease and healthy individuals.

A Krook, B Lindström, J Kjellander, G Järnerot, L Bodin.   

Abstract

Nine patients wih Crohn's disease and six healthy individuals were given 400 mg metronidazole twice daily and the concentration was measured in plasma and faeces 6 to 8 h after intake. Quantitative and qualitative bacteriological examinations were performed before and during treatment. The concentrations of metronidazole in plasma varied between 5 and 30 mg/l as measured by liquid chromatography (LC) and between 3 and 20 mg/l as measured by a bioassay (BA) method. There was no significant differences between the results of the two methods in patients but compared with BA the LC values were regularly lower in the healthy subjects. Metronidazole was detected in the faeces of most patients. These findings coincided with a significant reduction of Bacteroides spp in their faeces which was not apparent in healthy individuals in whom metronidazole was not detected in the faeces. Higher faecal metronidazole concentrations were found in patients with active disease and a total colon involvement as compared with the patients with a more quiescent disease and involvement of ileum and ascending colon only.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7251906      PMCID: PMC493641          DOI: 10.1136/jcp.34.6.645

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  14 in total

1.  An evaluation of metronidazole in the prophylaxis and treatment of anaerobic infections in surgical patients.

Authors: 
Journal:  J Antimicrob Chemother       Date:  1975-12       Impact factor: 5.790

2.  Bioavailability of metronidazole in fasting and non-fasting healthy subjects and in patients with Crohn's disease.

Authors:  A Melander; G Kahlmeter; C Kamme; B Ursing
Journal:  Eur J Clin Pharmacol       Date:  1977-08-17       Impact factor: 2.953

3.  In vitro effect of metronidazole and tinidazole on anaerobic bacteria.

Authors:  K Dornbusch; C E Nord
Journal:  Med Microbiol Immunol       Date:  1974       Impact factor: 3.402

4.  Comparative pharmacokinetic studies of ornidazole and metronidazole in man.

Authors:  D E Schwartz; F Jeunet
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

5.  Influence of neomycin and metronidazole on colonic microflora of volunteers.

Authors:  Y Arabi; F Dimock; D W Burdon; J Alexander-Williams; M R Keighley
Journal:  J Antimicrob Chemother       Date:  1979-09       Impact factor: 5.790

6.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.

Authors:  W R Best; J M Becktel; J W Singleton; F Kern
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

7.  Metronidazole in Crohn's disease. A double blind cross-over clinical trial.

Authors:  P Blichfeldt; J P Blomhoff; E Myhre; E Gjone
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

Review 8.  Metronidazole in anaerobic infections: a review of its activity, pharmacokinetics and therapeutic use.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1978-11       Impact factor: 9.546

9.  Metronidazole for Crohn's disease.

Authors:  B Ursing; C Kamme
Journal:  Lancet       Date:  1975-04-05       Impact factor: 79.321

10.  [Metronidazole circulation and fate in the digestive tract of the rat after oral administration. Absorption of metronidazole by the digestive mucosa].

Authors:  P Populaire; F Benazet; S Pascal; G Lebreton; B Decouvelaere; L Guillaume
Journal:  Therapie       Date:  1971 May-Jun       Impact factor: 2.070

View more
  12 in total

1.  A rapid, high-throughput viability assay for Blastocystis spp. reveals metronidazole resistance and extensive subtype-dependent variations in drug susceptibilities.

Authors:  Haris Mirza; Joshua D W Teo; Jacqui Upcroft; Kevin S W Tan
Journal:  Antimicrob Agents Chemother       Date:  2010-11-22       Impact factor: 5.191

Review 2.  Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases.

Authors:  Daniel A Peterson; Daniel N Frank; Norman R Pace; Jeffrey I Gordon
Journal:  Cell Host Microbe       Date:  2008-06-12       Impact factor: 21.023

3.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.

Authors:  H C Rath; H H Herfarth; J S Ikeda; W B Grenther; T E Hamm; E Balish; J D Taurog; R E Hammer; K H Wilson; R B Sartor
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli.

Authors:  H C Rath; K H Wilson; R B Sartor
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

5.  T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans.

Authors:  R Duchmann; E May; M Heike; P Knolle; M Neurath; K H Meyer zum Büschenfelde
Journal:  Gut       Date:  1999-06       Impact factor: 23.059

6.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

Authors:  R P Bolton; M A Culshaw
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

Review 7.  The dynamics of gut-associated microbial communities during inflammation.

Authors:  Sebastian E Winter; Christopher A Lopez; Andreas J Bäumler
Journal:  EMBO Rep       Date:  2013-03-12       Impact factor: 8.807

8.  Host-derived nitrate boosts growth of E. coli in the inflamed gut.

Authors:  Sebastian E Winter; Maria G Winter; Mariana N Xavier; Parameth Thiennimitr; Victor Poon; A Marijke Keestra; Richard C Laughlin; Gabriel Gomez; Jing Wu; Sara D Lawhon; Ina E Popova; Sanjai J Parikh; L Garry Adams; Renée M Tsolis; Valley J Stewart; Andreas J Bäumler
Journal:  Science       Date:  2013-02-08       Impact factor: 47.728

9.  Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases.

Authors:  Daniel N Frank; Allison L St Amand; Robert A Feldman; Edgar C Boedeker; Noam Harpaz; Norman R Pace
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-15       Impact factor: 11.205

Review 10.  The role of the intestinal context in the generation of tolerance and inflammation.

Authors:  Bernardo Sgarbi Reis; Daniel Mucida
Journal:  Clin Dev Immunol       Date:  2011-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.